Interstitial Photodynamic Therapy (PDT) for the Treatment of Patients with Locally Advanced or Recurrent Head and Neck Cancer

Preliminary experience suggests that porfimer sodium (Photofrin®) mediated interstitial photodynamic therapy (I-PDT) may hold promise for patients with locally advanced and recurrent head and neck cancer (HNC). Gal Shafirstein, DSc, MSc, BSc, Director of Photodynamic Therapy Clinical Research at Roswell Park, describes a new NCI/NIH funded Phase 1/2 clinical study (NCT03727061) that is now open to evaluate the safety and efficacy of adjuvant Photofrin® mediated I-PDT in patients with locally advanced or recurrent HNC who failed to respond to standard therapy and are not amenable to standard curative treatment. The video begins with background on I-PDT and rationale for the study, with the description of the study beginning around the 9:00 minute mark.

Created by

Roswell Park Comprehensive Cancer Center

Related Presenters

Gal Shafirstein, DSc, MSc, BSc

Gal Shafirstein, DSc, MSc, BSc

Professor of Oncology
Department of Cell Stress Biology
Director of PDT Clinical Research

EDUCATION AND TRAINING:  DSc, Technion, Israel Institute of Technology, Materials Science, 1988-1992 BSc, Ben Gurion University, Beer Sheva, Israel, Materials Science, 1982-86; M.Sc. Technion, Israel , 1986-88